CDKN1A and neoplasm: In our metastatic dataset along with additional primary SCLC patient tumor, circulating tumor cell‐derived xenograft, and patient‐derived xenograft (PDX) datasets, samples overexpressing MYC paralogs (MYC, MYCL, or MYCN) consistently displayed significantly lower CDKN1A expression (Fig 3H and Appendix Fig S2B).